Spots Global Cancer Trial Database for cladribine
Every month we try and update this database with for cladribine cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts | NCT05365035 | Myelodysplastic... Myeloproliferat... | Cladribine Cytarabine Venetoclax Azacitidine | 18 Years - | M.D. Anderson Cancer Center | |
| Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS | NCT02921061 | Mixed Phenotype... Previously Trea... Recurrent Adult... Recurrent High ... Refractory Acut... Refractory High... Untreated Adult... | Cladribine Cytarabine Decitabine Filgrastim Laboratory Biom... Mitoxantrone Hy... | 18 Years - | Fred Hutchinson Cancer Center | |
| Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma | NCT00980395 | Lymphoma Mantle Cell Lym... Indolent Lympho... SLL | rituximab bortezomib cladribine | 18 Years - | University of Arizona | |
| Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study | NCT04880746 | Peripheral T-ce... | BEAC Cladribine comb... | 18 Years - 65 Years | Ruijin Hospital | |
| Thiotepa, Cyclophosphamide, Clarithromycin and Cytarabine | NCT06060782 | Burkitt Lymphom... Lymphoblastic L... Acute Lymphobla... | Thiotepa, cyclo... | 18 Years - 65 Years | Fifth Affiliated Hospital, Sun Yat-Sen University | |
| A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL) | NCT00718549 | Lymphocytic Leu... | Cladribine Cyclophosphamid... Rituximab | 18 Years - | Hoffmann-La Roche | |
| Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | NCT04047641 | Acute Myeloid L... Blasts 20 Perce... High Risk Myelo... Recurrent Acute... Recurrent Acute... Recurrent High ... Refractory Acut... Refractory High... | Cladribine Cytarabine Idarubicin Quizartinib | 18 Years - | M.D. Anderson Cancer Center | |
| Bryostatin 1 Plus Cladribine in Treating Patients With Relapsed Chronic Lymphocytic Leukemia | NCT00003174 | Leukemia | bryostatin 1 cladribine | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children | NCT05313958 | Leukemia, Monoc... Pediatric AML | Cladribine G-CSF Cytarabine Idarubicin Mitoxantrone Sorafenib | 1 Month - 14 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts | NCT05365035 | Myelodysplastic... Myeloproliferat... | Cladribine Cytarabine Venetoclax Azacitidine | 18 Years - | M.D. Anderson Cancer Center | |
| Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated AML | NCT05053425 | Acute Myeloid L... | Venetoclax Azacitidine Cladribine Cytarabine Idarubicin | 60 Years - | LanZhou University | |
| Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study | NCT04880746 | Peripheral T-ce... | BEAC Cladribine comb... | 18 Years - 65 Years | Ruijin Hospital | |
| Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study | NCT04880746 | Peripheral T-ce... | BEAC Cladribine comb... | 18 Years - 65 Years | Ruijin Hospital | |
| Cladribine in Combination With CAG in Patients With Refractory/Relapsed Acute Myeloid Leukemia | NCT03181815 | Acute Myeloid L... Relapse Leukemi... | Cladribine G-CSF Aclarubicin Cytarabine | 15 Years - 75 Years | Sun Yat-sen University | |
| Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS | NCT04708054 | Acute Myeloid L... Chronic Myelomo... Myelodysplastic... | Busulfan Cladribine Fludarabine Pho... Hematopoietic C... Thiotepa Venetoclax | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS). | NCT05961644 | Multiple Sclero... Multiple Sclero... | Cladribine Subc... 0.9% Chloride I... | 30 Years - 65 Years | Institute of Psychiatry and Neurology, Warsaw | |
| Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia | NCT00412594 | Hairy Cell Leuk... Recurrent Hairy... | Cladribine Laboratory Biom... Rituximab | 18 Years - | M.D. Anderson Cancer Center | |
| Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma | NCT00980395 | Lymphoma Mantle Cell Lym... Indolent Lympho... SLL | rituximab bortezomib cladribine | 18 Years - | University of Arizona | |
| Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers | NCT03589729 | Acute Myeloid L... Blast Phase Chr... Blasts 10 Perce... High Risk Myelo... Myeloid Sarcoma Myeloproliferat... Philadelphia Ch... | Cladribine Cytarabine Dexrazoxane Hyd... Gemtuzumab Ozog... Idarubicin | 12 Years - | M.D. Anderson Cancer Center | |
| Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes | NCT02044796 | Acute Biphenoty... de Novo Myelody... Previously Trea... Recurrent Adult... Untreated Adult... Secondary Acute... | Cladribine Cytarabine Filgrastim Laboratory Biom... Mitoxantrone Hy... | 18 Years - | Fred Hutchinson Cancer Center | |
| Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study | NCT04880746 | Peripheral T-ce... | BEAC Cladribine comb... | 18 Years - 65 Years | Ruijin Hospital | |
| Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia | NCT02416908 | Acute Myeloid L... | Selinexor Cladribine G-CSF Cytarabine Bone marrow bio... | 18 Years - 70 Years | Washington University School of Medicine | |
| Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia | NCT04848974 | Secondary Acute... | Cladribine Cytarabine Uproleselan | 18 Years - | M.D. Anderson Cancer Center | |
| Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia | NCT06007911 | Relapsed Adult ... Refractory AML | Navitoclax Dose... Navitoclax Dose... Navitoclax Dose... Navitoclax Dose... Venetoclax Dose... Venetoclax Dose... Cladribine Cytarabine (Cla... Cytarabine (CLA... Mitoxantrone Granulocyte Col... | 18 Years - | Medical College of Wisconsin | |
| Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia | NCT00923013 | Hairy Cell Leuk... | Cladribine Rituximab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Cladribine in Combination With GAP in Patients With Refractory/Relapsed Acute Lymphoblastic Leukemia | NCT03318419 | Acute Lymphobla... | Cladribine G-CSF Cytarabine Pegaspargase | 18 Years - 80 Years | Sun Yat-sen University | |
| CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients | NCT04195945 | Acute Myeloid L... Myeloid Neoplas... | Liposome-encaps... Cladribine Cytarabine Recombinant Gra... Mitoxantrone Questionnaire A... Quality-of-Life... | 18 Years - | Fred Hutchinson Cancer Center | |
| Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | NCT02728050 | Acute Biphenoty... Acute Myeloid L... de Novo Myelody... Myelodysplastic... Myeloproliferat... | Cladribine Cytarabine Filgrastim Laboratory Biom... Quality-of-Life... Mitoxantrone Sorafenib | 18 Years - 60 Years | University of Washington | |
| CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia | NCT04375631 | Recurrent Acute... Recurrent Chron... Recurrent Myelo... Refractory Acut... Refractory Chro... Refractory Mixe... Refractory Myel... Refractory Acut... Refractory Acut... | Cladribine Cyclophosphamid... Cyclosporine Cytarabine Filgrastim Hematopoietic C... Mitoxantrone Mycophenolate M... Mycophenolate S... Total-Body Irra... Idarubicin Fludarabine Cytarabine Multigated Acqu... Echocardiograph... X-Ray Imaging Bone Marrow Bio... Bone Marrow Asp... | 18 Years - | Fred Hutchinson Cancer Center | |
| Rituximab and Cladribine in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma | NCT00053027 | Lymphoma | rituximab cladribine | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Treatment of Relapsed T-cell Acute Lymphoblastic Leukemia or T-lymphoblastic Lymphoma With MabCampath | NCT00199030 | Adult Acute Lym... Lymphoma, Lymph... | Alemtuzumab (Ma... Cladribine | 18 Years - | Goethe University | |
| Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm | NCT03012672 | Acute Leukemia ... Acute Myeloid L... Myeloid Neoplas... | Cladribine Cytarabine Granulocyte Col... Mitoxantrone Hy... Quality-of-Life... Questionnaire A... | 18 Years - | University of Washington | |
| Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia | NCT03586609 | Acute Myeloid L... | Azacitidine Cladribine Cytarabine Venetoclax | 50 Years - | M.D. Anderson Cancer Center | |
| A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL) | NCT00718549 | Lymphocytic Leu... | Cladribine Cyclophosphamid... Rituximab | 18 Years - | Hoffmann-La Roche | |
| Cladribine Combined With G-CSF and Cytarabine as a Salvage Treatment in R/R ALL | NCT05578378 | Acute Lymphobla... | Cladribine Fludarabine | 14 Years - | The First Affiliated Hospital of Soochow University | |
| Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | NCT02728050 | Acute Biphenoty... Acute Myeloid L... de Novo Myelody... Myelodysplastic... Myeloproliferat... | Cladribine Cytarabine Filgrastim Laboratory Biom... Quality-of-Life... Mitoxantrone Sorafenib | 18 Years - 60 Years | University of Washington | |
| Chemotherapy in Treating Children With Recurrent Acute Myeloid Leukemia | NCT00003178 | Leukemia | filgrastim cladribine idarubicin | - 21 Years | Children's Oncology Group | |
| A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine | NCT06021600 | Leukemia Myelodysplastic... Acute Myeloid L... | Cladribine | 18 Years - | M.D. Anderson Cancer Center | |
| Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | NCT00002805 | Leukemia | filgrastim cladribine cytarabine etoposide methotrexate mitoxantrone hy... therapeutic hyd... allogeneic bone... autologous bone... peripheral bloo... low-LET cobalt-... low-LET electro... low-LET photon ... | - 21 Years | Children's Oncology Group | |
| GM-CLAG in Relapsed/Refractory FLT3-mutated AML | NCT05330377 | Acute Myeloid L... | Gilteritinib 40... Cladribine Cytarabine Filgrastim Mitoxantrone | 18 Years - | University of Kentucky | |
| Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm | NCT03012672 | Acute Leukemia ... Acute Myeloid L... Myeloid Neoplas... | Cladribine Cytarabine Granulocyte Col... Mitoxantrone Hy... Quality-of-Life... Questionnaire A... | 18 Years - | University of Washington | |
| the Efficacy and Safety of CLAE in R/R T-ALL/LBL | NCT04679506 | Precursor T-Cel... | Cladribine | 18 Years - | Peking University Third Hospital | |
| Cladribine and Rituximab as Remission Induction Therapy Followed By Rituximab and Stem Cell Mobilization in Treating Patients With CLL | NCT00072007 | Leukemia | filgrastim rituximab CHOP regimen cladribine cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... | 18 Years - 65 Years | Swiss Group for Clinical Cancer Research | |
| Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS | NCT02921061 | Mixed Phenotype... Previously Trea... Recurrent Adult... Recurrent High ... Refractory Acut... Refractory High... Untreated Adult... | Cladribine Cytarabine Decitabine Filgrastim Laboratory Biom... Mitoxantrone Hy... | 18 Years - | Fred Hutchinson Cancer Center | |
| Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma | NCT00764517 | Recurrent B-Cel... Recurrent Chron... Recurrent Indol... Refractory B-Ce... | Cladribine Laboratory Biom... Rituximab Vorinostat | 18 Years - | OHSU Knight Cancer Institute | |
| Cladribine in Combination With GAP in Patients With Refractory/Relapsed Acute Lymphoblastic Leukemia | NCT03318419 | Acute Lymphobla... | Cladribine G-CSF Cytarabine Pegaspargase | 18 Years - 80 Years | Sun Yat-sen University | |
| Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AML | NCT01161550 | Leukemia, Myelo... | Granulocyte col... Cladribine Cytarabine All-Trans Retin... Midostaurin | 18 Years - | Washington University School of Medicine | |
| R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma | NCT01446900 | Chronic Lymphoc... Small Lymphocyt... | Rituximab Cladribine | 18 Years - | European Institute of Oncology | |
| Chemotherapy Followed by Radiation Therapy in Treating Patients With Malignant Glioma | NCT00019071 | Brain and Centr... | chemotherapy cladribine radiation thera... | 18 Years - | National Cancer Institute (NCI) | |
| Total Body Irradiation and Cladribine Before Allogeneic Hematopoietic Cell Transplantation in Patients With AML (Acute Myeloid Leukemia) and Myelodysplastic Syndromes | NCT04861207 | Acute Myeloid L... | Cladribine | 18 Years - 60 Years | Maria Sklodowska-Curie National Research Institute of Oncology | |
| Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes | NCT02044796 | Acute Biphenoty... de Novo Myelody... Previously Trea... Recurrent Adult... Untreated Adult... Secondary Acute... | Cladribine Cytarabine Filgrastim Laboratory Biom... Mitoxantrone Hy... | 18 Years - | Fred Hutchinson Cancer Center | |
| Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | NCT00002805 | Leukemia | filgrastim cladribine cytarabine etoposide methotrexate mitoxantrone hy... therapeutic hyd... allogeneic bone... autologous bone... peripheral bloo... low-LET cobalt-... low-LET electro... low-LET photon ... | - 21 Years | Children's Oncology Group | |
| GM-CLAG in Relapsed/Refractory FLT3-mutated AML | NCT05330377 | Acute Myeloid L... | Gilteritinib 40... Cladribine Cytarabine Filgrastim Mitoxantrone | 18 Years - | University of Kentucky | |
| Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma | NCT00787969 | Lymphoma | rituximab cladribine temsirolimus Filgrastim Pegfilgrastim | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma | NCT00787969 | Lymphoma | rituximab cladribine temsirolimus Filgrastim Pegfilgrastim | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm | NCT03531918 | Acute Myeloid L... | Cladribine Cytarabine Gemtuzumab Ozog... Recombinant Gra... Laboratory Biom... Mitoxantrone Hy... | 18 Years - | Fred Hutchinson Cancer Center | |
| Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children | NCT05313958 | Leukemia, Monoc... Pediatric AML | Cladribine G-CSF Cytarabine Idarubicin Mitoxantrone Sorafenib | 1 Month - 14 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia | NCT00923013 | Hairy Cell Leuk... | Cladribine Rituximab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Chidamide Combined With Clad/Gem/Bu With AutoSCT in R/R Diffuse Large B Cell Lymphoma | NCT03151876 | Lymphoma | Chidamide Cladribine gemcitabine Busulfan Autologous hema... | 18 Years - 60 Years | Sichuan University | |
| Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) | NCT01515527 | Leukemia | Cladribine Cytarabine Decitabine | 60 Years - | M.D. Anderson Cancer Center | |
| Study of Chidamide Combined With Cladribine in Refractory/Relapsed Acute Myeloid Leukemia | NCT05330364 | Acute Myeloid L... | Chidamide Cladribine | 18 Years - 75 Years | Zhongda Hospital | |
| Guadecitabine With or Without Idarubicin or Cladribine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | NCT02096055 | Untreated Adult... | Cladribine Guadecitabine Idarubicin | 70 Years - | M.D. Anderson Cancer Center | |
| Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS). | NCT05961644 | Multiple Sclero... Multiple Sclero... | Cladribine Subc... 0.9% Chloride I... | 30 Years - 65 Years | Institute of Psychiatry and Neurology, Warsaw | |
| Chidamide Combined With Clad/Gem/Bu With AutoSCT in High Risk Hodgkin & Non-Hodgkin Lymphoma | NCT03602131 | Hodgkin Lymphom... Non-hodgkin Lym... | Chidamide Cladribine gemcitabine Busulfan Autologous hema... | 15 Years - 65 Years | Sichuan University | |
| Cladribine, Cytarabine and Idarubicin in Patients With Relapsed Acute Myelocytic Leukemia (AML) | NCT00126321 | Leukemia, Myelo... | cladribine | 18 Years - | University Hospital, Bonn | |
| ChiCGB vs BEAM in High-risk or R/R Lymphomas | NCT05466318 | Lymphoma, Large... Lymphoma, T-Cel... | Chidamide Cladribine Gemcitabine Busulfan Carmustine Etoposide Cytarabine Melphalan Autologous hema... | 16 Years - 65 Years | Sichuan University | |
| Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers | NCT03589729 | Acute Myeloid L... Blast Phase Chr... Blasts 10 Perce... High Risk Myelo... Myeloid Sarcoma Myeloproliferat... Philadelphia Ch... | Cladribine Cytarabine Dexrazoxane Hyd... Gemtuzumab Ozog... Idarubicin | 12 Years - | M.D. Anderson Cancer Center | |
| Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia | NCT00258271 | Leukemia | filgrastim cladribine cytarabine imatinib mesyla... | 18 Years - | University of Rochester | |
| Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma | NCT00764517 | Recurrent B-Cel... Recurrent Chron... Recurrent Indol... Refractory B-Ce... | Cladribine Laboratory Biom... Rituximab Vorinostat | 18 Years - | OHSU Knight Cancer Institute | |
| Clofarabine in Chronic Lymphocytic Leukemia | NCT00028418 | Hematologic Neo... Lymphoprolifera... Leukemia Leukemia, Lymph... | Clofarabine | 18 Years - | FDA Office of Orphan Products Development | |
| Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms | NCT04797767 | Acute Biphenoty... Acute Myeloid L... Mixed Phenotype... Myeloid Neoplas... Relapsed Acute ... Relapsed Acute ... Relapsed Mixed ... Relapsed Myeloi... Refractory Acut... Refractory Acut... Refractory Mixe... Refractory Myel... Recurrent Myelo... | Cladribine Cytarabine Mitoxantrone Recombinant Gra... Venetoclax | 18 Years - | University of Washington | |
| Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS | NCT04708054 | Acute Myeloid L... Chronic Myelomo... Myelodysplastic... | Busulfan Cladribine Fludarabine Pho... Hematopoietic C... Thiotepa Venetoclax | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and Rituximab | NCT00667329 | Lymphoma | 2CdA Cyclophosphamid... Rituximab | - | M.D. Anderson Cancer Center | |
| Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AML | NCT01161550 | Leukemia, Myelo... | Granulocyte col... Cladribine Cytarabine All-Trans Retin... Midostaurin | 18 Years - | Washington University School of Medicine | |
| Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and Rituximab | NCT00667329 | Lymphoma | 2CdA Cyclophosphamid... Rituximab | - | M.D. Anderson Cancer Center | |
| Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers | NCT03589729 | Acute Myeloid L... Blast Phase Chr... Blasts 10 Perce... High Risk Myelo... Myeloid Sarcoma Myeloproliferat... Philadelphia Ch... | Cladribine Cytarabine Dexrazoxane Hyd... Gemtuzumab Ozog... Idarubicin | 12 Years - | M.D. Anderson Cancer Center | |
| Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia | NCT00258271 | Leukemia | filgrastim cladribine cytarabine imatinib mesyla... | 18 Years - | University of Rochester | |
| Guadecitabine With or Without Idarubicin or Cladribine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | NCT02096055 | Untreated Adult... | Cladribine Guadecitabine Idarubicin | 70 Years - | M.D. Anderson Cancer Center | |
| Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm | NCT03012672 | Acute Leukemia ... Acute Myeloid L... Myeloid Neoplas... | Cladribine Cytarabine Granulocyte Col... Mitoxantrone Hy... Quality-of-Life... Questionnaire A... | 18 Years - | University of Washington |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
